This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
by Zacks Equity Research
The GLISTEN study evaluating GSK's candidate, linerixibat, for treating cholestatic pruritus related to primary biliary cholangitis meets the primary endpoint.
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
by Zacks Equity Research
Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
by Zacks Equity Research
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
by Zacks Equity Research
EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
by Zacks Equity Research
Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Gilead (GILD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for MOAT
GILD or VRTX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GILD vs. VRTX: Which Stock Is the Better Value Option?
Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?
by Ekta Bagri
BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more room for growth, and any dip in share price can be used as a buying opportunity.
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook
by Zacks Equity Research
GILD's Q3 earnings and sales beat estimates on higher HIV, Veklury, oncology and liver disease drug sales. The stock is trading up.
Markets Tear Off the Lid in Hump-Day Trading
by Mark Vickery
A decisive win for Donald Trump and the Republican Party in both the White House and Congress will likely usher in very aggressive pro-business policies.
Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 27.85% and 7.94%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Pre-Markets Soar after Trump Wins U.S. Presidential Election
by Zacks Equity Research
Pre-Markets Soar after Trump Wins U.S. Presidential Election
Pre-Markets Surge on Historic Trump Victory
by Mark Vickery
The Dow is currently +1300 points, the S&P 500 +132, the Nasdaq +361 and the small-cap Russell 2000 +141 points.
Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow
by Zacks Equity Research
RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time acquisition cost and impairment charge on non-current assets.
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
by Kinjel Shah
Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.
Gilead Science to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on GILD???s HIV franchise performance and oncology sales when the company reports third-quarter 2024 results.
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) concluded the recent trading session at $88.82, signifying a +0.6% move from its prior day's close.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should VanEck Morningstar Wide Moat ETF (MOAT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MOAT
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Gilead Sciences (GILD) reachead $88.08 at the closing of the latest trading day, reflecting a -0.77% change compared to its last close.